Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 58 for “"DMARD"”.
-
Schwangerschaften von DMARD-exponierten Patienten mit juveniler idiopathischer Arthritis
… with disease modifying antirheumatic drugs (DMARDs) when they want to start a family. Little is known about the effects of DMARDs on pregnancy and its outcome, and most DMARDs are not approved for pregnant or breastfeeding women. Aim: To investigate the course and outcome of pregnancies in …
-
Caracterización epidemiológica de la artritis idiopática juvenil y refractariedad a dmard en una institución en Bogotá
… people a real challenge. Also, refractoriness to DMARDs (Disease - Modifying - Antirheumatic - Drugs) induces to the use of biological therapy and it may modify the prognosis of the disease. The epidemiological characterization of the pediatric population affected with this disease will get a …
-
Prediction to perfection? The added value of biomarkers in predicting DMARD response for rheumatoid arthritis patients
… Fortunately, effective medications, known as DMARDs, can reduce inflammation. However, not all patients respond well to the first treatment. This means that many must try multiple medications, a process that can take months. What if we could predict in advance which medication would work best …
-
Calprotectin bei DMARD (Disease Modifying Anti-Rheumatic Drug)-naiver früher rheumatoider Arthritis als Aktivitäts- und Verlaufsmarker unter Therapie
Die rheumatoide Arthritis ist die häufigste chronisch-entzündlich verlaufende Gelenkerkrankung. In der Pathogenese wird von einer systemischen Autoimmunerkrankung ausgegangen, die das angeborene und lernfähige Immunsystem einbezieht. Zur besseren Beurteilung der Krankheitsaktivität werden …
-
Schwangerschaften bei Patientinnen mit rheumatoider Arthritis unter Biologika-Therapie. Schwangerschaftskomplikationen und Schwangerschaftsverlauf im Vergleich zu Patientinnen unter konventionell synthetischer DMARD-Therapie
… unter konventionell synthetischer (cs)DMARD-Therapie in Hinblick auf Schwangerschaftskomplikationen und -verlauf verglichen. Von Interesse war die Beurteilung der Krankheitsaktivität zum Konzeptionszeitpunkt sowie des Krankheitsverlaufes während der Schwangerschaft, nach der Entbindung …
-
Factors associated with the initiation of biologic disease modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis
… biologic disease-modifying antirheumatic drugs (DMARDs), a class of medications that is the major cost driver in RA management. The main purpose of this study was to examine patient socio-demographics, medication use patterns, and clinical characteristics associated with initiation of biologic …
-
Comparative Effectiveness of Methotrexate-Based Disease-Modifying Antirheumatic Drug Combinations for Rheumatoid Arthritis
… (cs) disease-modifying antirheumatic drug (DMARD), tumor necrosis factor inhibitor (TNFi) biological (b) DMARD, non-TNFi bDMARD, or targeted synthetic (ts) DMARD for patients with rheumatoid arthritis (RA) initiating methotrexate (MTX); [2] to compare the effectiveness of MTX-based …
-
Einflussfaktoren auf den Verlauf interstitieller Lungenerkrankungen bei Patient:innen mit rheumatoider Arthritis
… disease-modifying anti-rheumatic drugs (DMARDs) consisting of csDMARDs, bDMARDs [tumour necrosis factor (TNFi), interleukin-6 inhibitors, T-cell inhibitors, B-cell-depleting therapies] and tsDMARDs, on mortality in RA-ILD are contradictory. Methods: All analyses are based on data from the …
-
Rekonstitution der prämaturen Immunoseneszenz-Parameter unter anti-TNF-alpha-Therapie bei juveniler idiopathischer Arthritis
… von JIA-Patienten - unterteilt in eine DMARD-Gruppe und eine TNFα-Inhibitor-Gruppe - mit denen von gesunden Vergleichsprobanden verglichen. Eine fortgeschrittenere Immunoseneszenz bei den Gesunden könnte möglicherweise durch vermehrte chronische Virusinfekte erklärt werden, die jedoch in …
-
Diagnosis and management of early inflammatory arthritis
… prompt disease-modifying anti-rheumatic drug (DMARD) therapy, treat-to-target strategies and use of biological therapies (bDMARDs) particularly following failure of conventional synthetic therapies (csDMARDs). Optimal use of bDMARDs in early disease, however, has not been established. Early …
-
Tailoring therapy to individual patient’s needs: intensive management of early rheumatoid arthritis using either clinical, laboratory or musculoskeletal ultrasound assessment of disease activity
… measures (such as the DAS28) and aggressive DMARD escalation until a lower disease activity target has been achieved. Imaging studies suggest that the DAS28 may be insensitive to low levels of subclinical active disease that is associated with an increased risk of flare and progressive joint …
-
Pneumococcal vaccination in inflammatory rheumatic disease and in splenectomy patients. From antibody response to memory cells.
… to disease-modifying antirheumatic drug (DMARD) treatments, and in postsplenectomy patients.Methods:(I) Splenectomized patients without previous pneumococcal conjugate vaccine (PCV) immunization were invited to receive one dose 13-valent PCV (PCV13). Blood was drawn before and 4-6 weeks …
-
Clinical and epigenetic factors underlying treatment refractory Rheumatoid Arthritis
… of standard therapies (disease modifying drugs (DMARD) and biologic therapies. This included a detailed examination of clinical characteristics, immune profile, inflammatory markers and burden of co-morbid complications such as vascular disease and depression. Outcomes such as disability, quality …
-
Die Sicherheit der Therapie mit Biologika bei rheumatoider Arthritis
… seit 2001 RA-Patienten mit Beginn einer neuen DMARD-Therapie einschließt. Alle Unter-suchungen umfassten eingehende Fallvalidierungen und die Bestimmung von Risikofaktoren sowie die Analyse des Einflusses der medikamentösen Therapie. Zusätzlich wurden Inzidenz-raten (IR) bestimmt (1+3). Die …
-
The development of randomised clinical trials in the treatment of rheumatoid arthritis over 20 years (1991 – 2011) in a single centre
… of disease modifying anti-rheumatic drugs (DMARDs). There had been few large, well conducted randomised controlled studies such that our knowledge about the relative efficacy and safety of the drugs available was very limited. Trial design also left much to be desired, with inadequate …
-
Epidemiology of herpes zoster in middle-aged and older Australians : the role of immunosuppressive conditions and therapies
… and disease-modifying antirheumatic drugs (DMARDs) – in a single population-based cohort. Methods Data from a prospective cohort of over 267,000 Australians aged 45 years and over (the Sax Institute’s 45 and Up Study) and linked pharmaceutical, hospital, medical service and death datasets …
-
Investigation and risk stratification of systemic sclerosis heart involvement
… and whether disease-modifying anti-rheumatic (DMARD) or vasodilator treatment can alter the course of pSSc-HI. The thesis demonstrates significant ILR findings especially in a poor prognosis group, supporting therefore the use of ILR in SSc patients. CMR-extracellular volume (ECV), marker of …
-
Changes in peripheral B cell subsets under immunosuppressive therapy
… therapy (disease modifying antirheumatic drugs (DMARDs)) and cyclophosphamide (CYC) treatment. There was a significant impact of immunosuppressive treatment on peripheral B cell subsets in SLE and WG patients. Absolute lymphocyte numbers and CD19+ B cell counts were significantly decreased, as …
-
Individualisation of leflunomide dosing in rheumatoid arthritis patients
… disease modifying anti-rheumatic drug (DMARD), initiated in those who fail to respond to methotrexate-based therapies. Nowadays, those who fail to respond to leflunomide tend to progress to expensive biological agents. Leflunomide’s therapeutic effects occur through the inhibition of the …
Page 1 of 3